For best experience please turn on javascript and use a modern browser!
You are using a browser that is no longer supported by Microsoft. Please upgrade your browser. The site may not present itself correctly if you continue browsing.
uva.nl
Swammerdam Institute for Life Sciences null

SILS Spin-offs

Within SILS, valorisation is valued and we stimulate new business opportunities. Several spinn-off initiatives were successfully started by our researchers.

Photanol

TRANSFORMING CO2 TO VALUABLE PRODUCTS, POWERED BY THE SUN

Photanol is a platform renewable chemicals company that utilises proprietary engineered cyanobacteria to process carbon dioxide (CO2) and sunlight into valuable chemical products.

Photanol recently got elected as Technology Pioneer at the World Economic Forum (WEF) held in China in 2019. 

 

Confocal.nl

Confocal.nl is aiming to innovate the microscopy industry with our plug-and-play feature confocal microscopes including the re-scan invention (Re-scan Confocal Microscope). Our new RCM-microscope  has an improved resolution and strongly improved sensitivity as compared to most confocal microscopes. It will be available as a highly affordable, customised device, which is ideal for labs with specific interests, or as an upgrade for existing wide-field fluorescence microscopes. Our goal is an open-architecture system that can be customised at need, and is platform- and software independent.

In 2019, Confocal.nl was one of the winners in the Academic Startup Competition. 

 

Macrobian-Biotech

Macrobian-Biotech was founded in May 2017 by Dr. Lars van der Heide and Prof. dr. Marten Smidt. Its primary goal is to perfect treatments for disorders of the midbrain dopamine system. The company is currently housed at the University of Amsterdam, the heart of academic excellence in the Netherlands.

Macrobian Biotech utilizes state of the art technology and is at the very front of scientific breakthroughs. The company's step-by-step mechanistic approach to unravel molecular components of dopamine neurons has lead to the identification of compounds that are able to restore dopamine production. The constant perfectioning and
upgrading of such compounds is the current core business of Macrobian-Biotech. Its perspective is to deliver a fully tested and safe compound to be verified in clinical trials for neurodegenerative diseases as Parkinson.